CFFP
NAVB

Center for Financial Planning’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Center for Financial Planning’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-9
Closed – – 544
2021
Q2 		$0 Buy
+9
New +$16 ﹤0.01% 562

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Center for Financial Planning's NAVB Position: Q3 2021 in Review

Center for Financial Planning sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q3 2021, closing a stake of 9 shares.

Center for Financial Planning first reported a position in NAVB in Q2 2021 and held it in 1 quarter. The position peaked at $0 in Q2 2021. 29 funds tracked by Wall St. Rank hold NAVB as of Q3 2021.

  • Center for Financial Planning reported no remaining Navidea Biopharmaceuticals Inc. position as of Q3 2021 after selling out during the quarter.
  • Center for Financial Planning sold 9 Navidea Biopharmaceuticals Inc. shares in Q3 2021.
  • Center for Financial Planning first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2021 and held it in 1 quarter.
  • Center for Financial Planning's Navidea Biopharmaceuticals Inc. position peaked at $0 in Q2 2021.
  • 29 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2021.

Based on Center for Financial Planning's 13F filing for Q3 2021, filed 27 Oct 2021.